US generics manufacturer Amneal Pharmaceuticals (Amneal) and biosimilar specialist mAbxience, a subsidiary of Spanish healthcare firm Insud Pharma (formerly Chemo Group), announced on May 23, 2018 that they had entered into an exclusive supply and license agreement in US for biosimilar mAbxience candidate bevacizumab.